People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Pharmaceuticals, Other Health Care, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Emmaus Life Sciences, Inc. | — | Pharmaceuticals | Series B | $102.9M | $2.9M | 2010 |
| ConnectRN, Inc. | — | Other Health Care | Series C | $102.7M | $1.2B | 2017 |
| Cancer Genetics, Inc | — | Biotechnology | Series A | $33.1M | $272.0M | 2010 |
| Pharmathene, Inc | — | Other | Series B | $29.2M | $164.4M | 2009 |
| OneroRx, Inc. | — | Other | Series B | $20.0M | $211.6M | 2022 |
| SyncBak, Inc. | — | Other | Series A | $17.7M | $30.3M | 2013 |
| Spectrascience Inc | — | Other Health Care | Seed | $7.9M | $31.0M | 2009 |
| American CareSource Holdings, Inc. | — | Other Health Care | Seed | $7.6M | $12.6M | 2014 |
| Telemynd, Inc. | — | Other Health Care | Series A | $6.0M | $51.0M | 2022 |
| St. Gregory Centers Holdings, LLC | — | Other Health Care | Seed | $1.0M | $24.8M | 2012 |
John Pappajohn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Pappajohn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tommy Thompson | 2 | 5 |
| Geoffrey Harris | 2 | 4 |
| Richard W. Turner | 2 | 2 |
| Shelley Boyce | 2 | 2 |
| David Jones | 1 | 19 |
| William Sullivan | 1 | 13 |
| Michael Wood | 1 | 10 |
| Matthew P. Kinley | 1 | 6 |
| Geoff Harris | 1 | 5 |
| Steven St. Peter | 1 | 4 |
| Andrew Pecora | 1 | 4 |
| Robin Smith | 1 | 4 |
| Matthew Kinley | 1 | 4 |
| Mark McWilliams | 1 | 4 |
| Daniel Hoffman | 1 | 4 |
| Derace L Schaffer | 1 | 4 |
| David B. Jones | 1 | 3 |
| Edward Wilson | 1 | 3 |
| Amir F. Heshmatpour | 1 | 3 |
| Mark Oman | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.